GlassScriptPhysician profile
Christopher C Lee
NPI 1356334866
$4,860.24
in general payments reported to CMS, 2019-2025
37 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $709 · 2021: $732 · 2022: $774 · 2023: $590 · 2024: $475 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $612.92 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $395.32 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $342.61 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.56 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $287.90 | 2019-2024 | |
| Lilly USA, LLC | $286.79 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $254.68 | 2021-2023 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $227.07 | 2019-2025 | |
| Amgen INC. | $206.68 | 2019-2025 | Repatha, Otezla, Otezla |
| Genentech USA, INC. | $127.08 | 2019-2020 | |
| Exact Sciences Corporation | $121.66 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $112.58 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $107.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $104.53 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.